The antimicrobial resistance diagnostics market size has grown strongly in recent years. It will grow from $4.41 billion in 2025 to $4.74 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing prevalence of antibiotic-resistant infections, reliance on conventional culture-based diagnostics, rising hospital-acquired infections, growing awareness of antimicrobial stewardship, expansion of clinical microbiology laboratories.
The antimicrobial resistance diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to advancement in pcr and ngs diagnostic technologies, increasing government funding for amr surveillance programs, rising adoption of rapid diagnostic tests, growth in pharmaceutical and biotechnology research, integration of data-driven decision support tools. Major trends in the forecast period include rising adoption of rapid and point-of-care amr diagnostics, growing demand for targeted and personalized antimicrobial therapy, increased surveillance of drug-resistant pathogens, expansion of molecular and genomic-based diagnostic testing, strengthening of hospital infection control and stewardship programs.
The increasing incidence of drug-resistant infections is expected to drive the growth of the antimicrobial resistance diagnostics market in the coming years. These infections occur when bacteria, viruses, fungi, or parasites develop mechanisms to survive medications that were previously effective, making standard treatments less effective and infections harder to control. The rise in drug-resistant infections is largely linked to the overuse of antibiotics in agriculture, where low-dose antimicrobials are routinely added to animal feed, promoting resistance that can spread to humans through the food chain. Antimicrobial resistance diagnostics, such as rapid genetic assays and culture-based sensitivity tests, play a key role in addressing this challenge by enabling early detection of resistant pathogens, guiding targeted therapies, and reducing the misuse of broad-spectrum antibiotics. For instance, in November 2024, the UK Health Security Agency (UKHSA) reported that serious antibiotic-resistant infections in England increased from 58,224 in 2022 to an estimated 66,730 in 2023, while antibiotic usage rose to 2.4% over the same period, highlighting how the growing prevalence of drug-resistant infections is driving the expansion of the antimicrobial resistance diagnostics market.
Major companies operating in the antimicrobial resistance (AMR) diagnostics market are emphasizing the use of advanced technologies such as point-of-care antimicrobial-susceptibility testing (AST) solutions to improve diagnostic speed, accuracy, and antimicrobial stewardship outcomes. Point-of-care antimicrobial-susceptibility testing (AST) involves rapid, near-patient testing that identifies which antibiotics are effective against an infection, enabling clinicians to promptly select targeted treatments. For example, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, introduced the PA-100 AST System, a point-of-care rapid AST platform capable of detecting bacterial presence and determining antimicrobial susceptibility in urine samples in about 30 minutes. The system incorporates microfluidic single-cell analysis, near-patient testing functionality, and automated reporting of susceptibility results. The PA-100 AST System enhances clinical decision-making, minimizes unnecessary antibiotic use, and facilitates timely, targeted therapy to address antimicrobial resistance.
In June 2025, bioMérieux, a France-based provider of in vitro diagnostic (IVD) solutions and infectious disease testing technologies, acquired the assets of Day Zero Diagnostics for an undisclosed amount. Through this acquisition, bioMérieux obtains access to Day Zero Diagnostics’ next-generation sequencing (NGS) workflows, NGS chemistries, bioinformatics pipeline, and AI-driven antimicrobial resistance (AMR) prediction technologies, thereby enhancing its next-generation antimicrobial resistance diagnostics capabilities and strengthening its innovation pipeline in rapid pathogen identification and antimicrobial susceptibility testing (AST). Day Zero Diagnostics is a US-based developer of sequencing-based infectious disease diagnostic technologies.
Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc.
North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antimicrobial resistance diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the antimicrobial resistance diagnostics market by increasing the cost of imported instruments, reagents, and advanced molecular testing equipment such as pcr and ngs systems. Kits and reagents along with high-end diagnostic instruments are most affected, particularly in asia-pacific and emerging markets that depend heavily on imported technologies. These cost pressures can slow adoption in smaller laboratories and healthcare facilities. However, tariffs are also encouraging local manufacturing, regional sourcing of consumables, and investments in domestic diagnostic production capabilities, supporting long-term market sustainability.
The antimicrobial resistance diagnostics market research report is one of a series of new reports that provides antimicrobial resistance diagnostics market statistics, including antimicrobial resistance diagnostics industry global market size, regional shares, competitors with a antimicrobial resistance diagnostics market share, detailed antimicrobial resistance diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial resistance diagnostics industry. This antimicrobial resistance diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Antimicrobial resistance (AMR) diagnostics are tests designed to detect microorganisms that have developed resistance to antibiotics or other antimicrobial agents. These diagnostics identify the specific pathogen and determine its resistance or susceptibility to various drugs, enabling targeted and effective treatment. AMR diagnostics play a crucial role in controlling the spread of resistant infections and guiding appropriate antimicrobial use in both clinical and public health settings.
The primary product types in the antimicrobial resistance diagnostics market include kits and reagents, instruments, and consumables. Kits and reagents consist of standardized chemicals and biological materials used to detect or measure specific pathogens or substances in diagnostic tests. These diagnostics target various pathogens such as drug-resistant Streptococcus pneumoniae (DRSP), drug-resistant Campylobacter (DRC), Clostridium difficile (CD), methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant Neisseria gonorrhoeae (DRNG), drug-resistant Salmonella (DRNTS), and other resistant organisms. A variety of technologies are employed, including microbiology culture, immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), mass spectrometry, rapid and point-of-care testing, and others. Key end users include hospitals and clinics, diagnostic laboratories, research institutes, pharmaceutical and biotechnology companies, among others.
The antimicrobial resistance diagnostics market consists of revenues earned by entities by providing services such as pathogen identification, resistance gene detection, rapid screening, antimicrobial susceptibility testing, and diagnostic data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The antimicrobial resistance diagnostics market includes sales of polymerase chain reaction (PCR) instruments, immunoassay kits, point-of-care testing devices, sequencing reagents, and microbiology culture consumables. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The antimicrobial resistance diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to advancement in pcr and ngs diagnostic technologies, increasing government funding for amr surveillance programs, rising adoption of rapid diagnostic tests, growth in pharmaceutical and biotechnology research, integration of data-driven decision support tools. Major trends in the forecast period include rising adoption of rapid and point-of-care amr diagnostics, growing demand for targeted and personalized antimicrobial therapy, increased surveillance of drug-resistant pathogens, expansion of molecular and genomic-based diagnostic testing, strengthening of hospital infection control and stewardship programs.
The increasing incidence of drug-resistant infections is expected to drive the growth of the antimicrobial resistance diagnostics market in the coming years. These infections occur when bacteria, viruses, fungi, or parasites develop mechanisms to survive medications that were previously effective, making standard treatments less effective and infections harder to control. The rise in drug-resistant infections is largely linked to the overuse of antibiotics in agriculture, where low-dose antimicrobials are routinely added to animal feed, promoting resistance that can spread to humans through the food chain. Antimicrobial resistance diagnostics, such as rapid genetic assays and culture-based sensitivity tests, play a key role in addressing this challenge by enabling early detection of resistant pathogens, guiding targeted therapies, and reducing the misuse of broad-spectrum antibiotics. For instance, in November 2024, the UK Health Security Agency (UKHSA) reported that serious antibiotic-resistant infections in England increased from 58,224 in 2022 to an estimated 66,730 in 2023, while antibiotic usage rose to 2.4% over the same period, highlighting how the growing prevalence of drug-resistant infections is driving the expansion of the antimicrobial resistance diagnostics market.
Major companies operating in the antimicrobial resistance (AMR) diagnostics market are emphasizing the use of advanced technologies such as point-of-care antimicrobial-susceptibility testing (AST) solutions to improve diagnostic speed, accuracy, and antimicrobial stewardship outcomes. Point-of-care antimicrobial-susceptibility testing (AST) involves rapid, near-patient testing that identifies which antibiotics are effective against an infection, enabling clinicians to promptly select targeted treatments. For example, in June 2023, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, introduced the PA-100 AST System, a point-of-care rapid AST platform capable of detecting bacterial presence and determining antimicrobial susceptibility in urine samples in about 30 minutes. The system incorporates microfluidic single-cell analysis, near-patient testing functionality, and automated reporting of susceptibility results. The PA-100 AST System enhances clinical decision-making, minimizes unnecessary antibiotic use, and facilitates timely, targeted therapy to address antimicrobial resistance.
In June 2025, bioMérieux, a France-based provider of in vitro diagnostic (IVD) solutions and infectious disease testing technologies, acquired the assets of Day Zero Diagnostics for an undisclosed amount. Through this acquisition, bioMérieux obtains access to Day Zero Diagnostics’ next-generation sequencing (NGS) workflows, NGS chemistries, bioinformatics pipeline, and AI-driven antimicrobial resistance (AMR) prediction technologies, thereby enhancing its next-generation antimicrobial resistance diagnostics capabilities and strengthening its innovation pipeline in rapid pathogen identification and antimicrobial susceptibility testing (AST). Day Zero Diagnostics is a US-based developer of sequencing-based infectious disease diagnostic technologies.
Major companies operating in the antimicrobial resistance diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, bioMerieux SA, Sysmex Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Seegene Inc, Alifax S r l, Accelerate Diagnostics Inc, Molsid SAS, Genetic Signatures Limited, iFAST Diagnostics Ltd, Astek Diagnostics Inc, OpGen Inc, T2 Biosystems, Jiangsu Medomics Medical Technology Co Ltd, Cepheid, Luminex Corporation, Bruker Corporation, Hologic Inc.
North America was the largest region in the antimicrobial resistance diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antimicrobial resistance diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antimicrobial resistance diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the antimicrobial resistance diagnostics market by increasing the cost of imported instruments, reagents, and advanced molecular testing equipment such as pcr and ngs systems. Kits and reagents along with high-end diagnostic instruments are most affected, particularly in asia-pacific and emerging markets that depend heavily on imported technologies. These cost pressures can slow adoption in smaller laboratories and healthcare facilities. However, tariffs are also encouraging local manufacturing, regional sourcing of consumables, and investments in domestic diagnostic production capabilities, supporting long-term market sustainability.
The antimicrobial resistance diagnostics market research report is one of a series of new reports that provides antimicrobial resistance diagnostics market statistics, including antimicrobial resistance diagnostics industry global market size, regional shares, competitors with a antimicrobial resistance diagnostics market share, detailed antimicrobial resistance diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial resistance diagnostics industry. This antimicrobial resistance diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Antimicrobial resistance (AMR) diagnostics are tests designed to detect microorganisms that have developed resistance to antibiotics or other antimicrobial agents. These diagnostics identify the specific pathogen and determine its resistance or susceptibility to various drugs, enabling targeted and effective treatment. AMR diagnostics play a crucial role in controlling the spread of resistant infections and guiding appropriate antimicrobial use in both clinical and public health settings.
The primary product types in the antimicrobial resistance diagnostics market include kits and reagents, instruments, and consumables. Kits and reagents consist of standardized chemicals and biological materials used to detect or measure specific pathogens or substances in diagnostic tests. These diagnostics target various pathogens such as drug-resistant Streptococcus pneumoniae (DRSP), drug-resistant Campylobacter (DRC), Clostridium difficile (CD), methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant Neisseria gonorrhoeae (DRNG), drug-resistant Salmonella (DRNTS), and other resistant organisms. A variety of technologies are employed, including microbiology culture, immunoassay, polymerase chain reaction (PCR), next-generation sequencing (NGS), mass spectrometry, rapid and point-of-care testing, and others. Key end users include hospitals and clinics, diagnostic laboratories, research institutes, pharmaceutical and biotechnology companies, among others.
The antimicrobial resistance diagnostics market consists of revenues earned by entities by providing services such as pathogen identification, resistance gene detection, rapid screening, antimicrobial susceptibility testing, and diagnostic data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The antimicrobial resistance diagnostics market includes sales of polymerase chain reaction (PCR) instruments, immunoassay kits, point-of-care testing devices, sequencing reagents, and microbiology culture consumables. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Antimicrobial Resistance Diagnostics Market Characteristics
3. Antimicrobial Resistance Diagnostics Market Supply Chain Analysis
4. Global Antimicrobial Resistance Diagnostics Market Trends and Strategies
5. Antimicrobial Resistance Diagnostics Market Analysis of End Use Industries
7. Global Antimicrobial Resistance Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Antimicrobial Resistance Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Antimicrobial Resistance Diagnostics Market Segmentation
10. Antimicrobial Resistance Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Antimicrobial Resistance Diagnostics Market
12. China Antimicrobial Resistance Diagnostics Market
13. India Antimicrobial Resistance Diagnostics Market
14. Japan Antimicrobial Resistance Diagnostics Market
15. Australia Antimicrobial Resistance Diagnostics Market
16. Indonesia Antimicrobial Resistance Diagnostics Market
17. South Korea Antimicrobial Resistance Diagnostics Market
18. Taiwan Antimicrobial Resistance Diagnostics Market
19. South East Asia Antimicrobial Resistance Diagnostics Market
20. Western Europe Antimicrobial Resistance Diagnostics Market
21. UK Antimicrobial Resistance Diagnostics Market
22. Germany Antimicrobial Resistance Diagnostics Market
23. France Antimicrobial Resistance Diagnostics Market
24. Italy Antimicrobial Resistance Diagnostics Market
25. Spain Antimicrobial Resistance Diagnostics Market
26. Eastern Europe Antimicrobial Resistance Diagnostics Market
27. Russia Antimicrobial Resistance Diagnostics Market
28. North America Antimicrobial Resistance Diagnostics Market
29. USA Antimicrobial Resistance Diagnostics Market
30. Canada Antimicrobial Resistance Diagnostics Market
31. South America Antimicrobial Resistance Diagnostics Market
32. Brazil Antimicrobial Resistance Diagnostics Market
33. Middle East Antimicrobial Resistance Diagnostics Market
34. Africa Antimicrobial Resistance Diagnostics Market
36. Antimicrobial Resistance Diagnostics Market Competitive Landscape and Company Profiles
37. Antimicrobial Resistance Diagnostics Market Other Major and Innovative Companies
40. Antimicrobial Resistance Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Antimicrobial Resistance Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses antimicrobial resistance diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for antimicrobial resistance diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antimicrobial resistance diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Kits And Reagents; Instruments And Consumables2) By Pathogen: Drug-Resistant Streptococcus Pneumoniae (DRSP); Drug Resistant Campylobacter (DRC); Clostridium Difficile (CD); Methicillin Resistant Staphylococcus Aureus (MRSA); Drug Resistant Neisseria Gonorrhoeae (DRNG); Drug Resistant Salmonella (DRntS); Other Pathogens
3) By Technology: Microbiology Culture; Immunoassay; PCR (Polymerase Chain Reaction); NGS (Next-Generation Sequencing); Mass Spectrometry; Rapid And Point Of Care; Other Technologies
4) By End-User: Hospitals And Clinics; Diagnostics Laboratories; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
Subsegments:
1) By Kits And Reagents: Deoxyribonucleic Acid (DNA) Extraction Kits; Ribonucleic Acid (RNA) Extraction Kits; Polymerase Chain Reaction (PCR) Reagents; Immunoassay Reagents; Stains And Dyes; Culture Media2) By Instruments And Consumables: Polymerase Chain Reaction (PCR) Machines; Ultraviolet-Visible (UV-Vis) Spectrophotometers; Next-Generation Sequencing (NGS) Systems; Microarray Scanners; Automated Liquid Handlers; Sample Collection Tubes And Swabs
Companies Mentioned: F Hoffmann La Roche AG; Thermo Fisher Scientific Inc; Abbott Laboratories; Danaher Corporation; Becton Dickinson And Company; bioMerieux SA; Sysmex Corporation; Bio Rad Laboratories Inc; QIAGEN NV; Seegene Inc; Alifax S r l; Accelerate Diagnostics Inc; Molsid SAS; Genetic Signatures Limited; iFAST Diagnostics Ltd; Astek Diagnostics Inc; OpGen Inc; T2 Biosystems; Jiangsu Medomics Medical Technology Co Ltd; Cepheid; Luminex Corporation; Bruker Corporation; Hologic Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Antimicrobial Resistance Diagnostics market report include:- F Hoffmann La Roche AG
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Danaher Corporation
- Becton Dickinson And Company
- bioMerieux SA
- Sysmex Corporation
- Bio Rad Laboratories Inc
- QIAGEN NV
- Seegene Inc
- Alifax S r l
- Accelerate Diagnostics Inc
- Molsid SAS
- Genetic Signatures Limited
- iFAST Diagnostics Ltd
- Astek Diagnostics Inc
- OpGen Inc
- T2 Biosystems
- Jiangsu Medomics Medical Technology Co Ltd
- Cepheid
- Luminex Corporation
- Bruker Corporation
- Hologic Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.74 Billion |
| Forecasted Market Value ( USD | $ 6.23 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
